| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
|
| | 11,12-dihydro-4-methoxydibenz(b,f)(1,4)oxazepine-8-carboxylate Basic information |
| Product Name: | 11,12-dihydro-4-methoxydibenz(b,f)(1,4)oxazepine-8-carboxylate | | Synonyms: | 11,12-dihydro-4-methoxydibenz(b,f)(1,4)oxazepine-8-carboxylate;AZ-1355
(NSC 364889;Dibenz[b,f][1,4]oxazepine-8-carboxylic acid, 10,11-dihydro-4-methoxy-, ethyl ester;AZ1355,AZ 1355;AZ-1355, 10 mM in DMSO | | CAS: | 75451-07-9 | | MF: | C17H17NO4 | | MW: | 299.32 | | EINECS: | | | Product Categories: | | | Mol File: | 75451-07-9.mol |  |
| | 11,12-dihydro-4-methoxydibenz(b,f)(1,4)oxazepine-8-carboxylate Chemical Properties |
| storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | form | Solid | | color | White to off-white |
| | 11,12-dihydro-4-methoxydibenz(b,f)(1,4)oxazepine-8-carboxylate Usage And Synthesis |
| Uses | AZ-1355 is an effctive lipid-lowering compound, which also inhibits platelet aggregation in vivo and elevates the prostaglandin I2/thromboxane A2 ratio in vitro. | | in vivo | AZ-1355 (50 mg/kg) significantly reduces serum TG and the 100 mg/kg dose results in serum TC and TG reduction in rat. AZ-1355 (100 mg/kg) reduces total liver TC in rats fed CE-2, and the 50 mg/kg dose reduces hepatic TC in rats fed the high fat diet on both bases, and it also reduces the total hepatic TG of the CE-2 fed rats. AZ-1355 (150 mg/kg) reproducibly lowers serum total cholesterol (TC) in the Triton hyperlipidemic mice[1]. | | IC 50 | TXA2/TP; Prostaglandin I2 | | References | [1] Wada S, et al. The lipid-lowering profile in rodents. AZ-1355, a new dibenzoxazepine derivative. Atherosclerosis. 1981 Nov-Dec;40(3-4):263-71. DOI:10.1016/0021-9150(81)90136-2
[2] Wada S, et al. The lipid-lowering profile in rodents. AZ-1355, a new dibenzoxazepine derivative. Atherosclerosis. 1981 Nov-Dec;40(3-4):263-71. |
| | 11,12-dihydro-4-methoxydibenz(b,f)(1,4)oxazepine-8-carboxylate Preparation Products And Raw materials |
|